DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

On Thursday, genetics-led consumer healthcare company 23andMe Holding Co. (NASDAQ:ME) announced a business restructuring to ...

This eases the user's understanding of the market thoroughly, while also gaining knowledge about Anxiety Disorder Treatment market opportunities and the dominant players Pfizer Inc, Merck KGaA, Sanofi ...

GSK plc has an exclusive global license option to co-develop and commercialize XMT-2056. At the Society for Immunotherapy of ...

Consider taking independent financial advice. Mark Hartley has positions in AstraZeneca Plc and GSK. The Motley Fool UK has recommended AstraZeneca Plc, GSK, Rolls-Royce Plc, Tesla, and Workday. Views ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

Check the time stamp on this data. Updated AI-Generated Signals for Gsk Plc American Depositary Shares (each Representing Two ...

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...